为便于广大投资者进一步了解西藏奇正藏药股份有限公司（以下简称"公 司"）经营情况，公司定于2023年5月12日（星期五）15:00—17:00在"奇正藏 药投资者关系"小程序举行2022年度报告业绩说明会，就公司发展战略、生产经 营情况与投资者进行充分交流，广泛听取投资者的意见和建议。 届时出席本次业绩说明会的人员有：公司董事、总裁刘凯列先生，副总裁李 军先生，副总裁、董事会秘书冯平女士，财务总监姚晓梅女士，副总裁赵敏女士， 独立董事李春瑜先生。 本次业绩说明会采用网络远程的方式举行，为广泛听取投资者的意见和建 议，提前向投资者征集问题，提问通道自发出公告之日起开放，投资者可通过以 下方式参与互动交流。 参与方式一：微信扫一扫"奇正藏药投资者关系平台"微信公众号二维码， 在"投关"中进入投资者关系活动，即可参与交流； | 证券代码：002287 | 证券简称：奇正藏药 | 公告编号：2023-021 | | --- | --- | --- | | 债券代码：128133 | 债券简称：奇正转债 | | 西藏奇正藏药股份有限公司 关于举行 2022 年度报告业绩说明会的公告 本公司及董事会全体成员保证信息披露内 ...

证券代码：002287 证券简称：奇正藏药 公告编号：2023-019 债券代码：128133 债券简称：奇正转债 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 3.第一季度报告是否经审计 （一） 主要会计数据和财务指标 | --- | --- | --- | --- | |-----------------------------------------------------|-----------------|----------------|--------------------------------| | | 本报告期 | 上年同期 | 减（%） | | 营业收入（元） | 295,933,466.90 | 407,575,576.83 | -27.39% | | 归属于上市公司股东的净利润 （元） | 92,763,157.33 | 87,085,414.41 | 6.52% | | 归属于上市公司股东的扣除非经 常性损益的净利润（元） | 31,579,085.46 | 117,686,008.81 | -73.17% | | 经营活动产生 ...

Financial Performance - The company's operating revenue for 2022 was CNY 2,044,789,340.21, representing a 15.49% increase compared to CNY 1,770,485,989.72 in 2021[12]. - The net profit attributable to shareholders for 2022 was CNY 440,018,192.00, which is a 27.57% increase from CNY 344,932,156.80 in 2021[12]. - The basic earnings per share for 2022 decreased to CNY 0.8919, down 34.14% from CNY 1.3542 in 2021[12]. - The net cash flow from operating activities for 2022 was CNY 285,686,729.21, a decrease of 72.40% compared to CNY 1,034,917,529.72 in 2021[12]. - The company reported a net loss from the disposal of non-current assets amounting to -159,828.88 yuan in 2022, compared to a profit of 72,823,720.13 yuan in 2021, indicating a significant decline in asset disposal performance[38]. - The fair value changes and disposal gains from trading financial assets amounted to 41,611,008.20 yuan in 2022, up from 28,662,428.66 yuan in 2021, reflecting improved trading performance[38]. - The company experienced a substantial decrease in other non-operating income and expenses, reporting -52,785,637.84 yuan in 2022, down from 294,826,622.00 yuan in 2021, primarily due to equity investment losses[38]. - The tax impact of non-recurring gains and losses was 4,193,302.39 yuan in 2022, compared to 38,796,178.22 yuan in 2021, indicating a reduced tax burden from non-recurring items[38]. - Investment income decreased by ¥33,652,366.41, accounting for -6.48% of total profit due to losses from long-term equity investments and financial products[93]. - Fair value changes resulted in a loss of ¥3,429,422.25, representing -0.66% of total profit, attributed to the measurement of trading financial assets at fair value[93]. - Other income increased to ¥72,995,779.05, making up 14.06% of total profit, primarily from government subsidies and deferred income[93]. Assets and Liabilities - The total assets at the end of 2022 were CNY 5,886,644,252.44, a 5.73% increase from CNY 5,567,753,848.57 at the end of 2021[12]. - Cash and cash equivalents at the end of 2022 were ¥437,571,379.17, constituting 7.43% of total assets, down from 11.97% at the beginning of the year[93]. - Accounts receivable rose to ¥102,418,409.81, representing 1.74% of total assets, an increase of 1.19% compared to the beginning of the year[93]. - Inventory increased to ¥127,774,134.44, accounting for 2.17% of total assets, a slight rise from 2.13% at the beginning of the year[93]. - The total amount of financial assets at the end of the period was ¥2,888,316,080.27, with a fair value change loss of -¥3,123,054.96[94]. Research and Development - The company holds 155 patents, including 126 invention patents, and was ranked 31st in the "2022 China Traditional Chinese Medicine R&D Strength Ranking TOP50"[22]. - The company is actively involved in the research and development of traditional Tibetan medicine, aiming to modernize and industrialize its offerings[84]. - The company is focusing on modernizing traditional Tibetan medicine, enhancing product quality, and expanding clinical applications to improve patient safety and efficacy[44]. - The company is building a digital platform for R&D management and an integrated R&D platform for Tibetan medicine products[142]. - The company launched the "Demonstration Development Research of Tibetan Medicine for Major Diseases" and completed the research work, providing Tibetan medicine solutions for acute stroke and diabetic peripheral neuropathy[139]. - The company published 15 SCI articles and had products like pain relief patches and Qingpeng ointment included in 18 guidelines/expert consensus documents[139]. Market Strategy and Product Development - The company plans to expand its product offerings, which currently include 141 approved products, focusing on external and oral Tibetan medicine[24]. - The company has developed a marketing strategy to promote traditional Tibetan medicine in mainstream markets and retail pharmacies, increasing brand recognition among consumers[47]. - The company offers a range of products, including pain relief patches and oral medications, with several items covered by national medical insurance, enhancing market access[45]. - The company aims to optimize its product indications and marketing strategies through evidence-based medicine research, targeting specific therapeutic areas[47]. - The company focuses on the advantages of Tibetan medicine, continuously enriching its product line, with pain relief products like pain relief patches and Qingpeng ointment seeing sustained sales growth[138]. - The pain relief patch has maintained its position as one of the top three external traditional Chinese medicine products in orthopedics, with a compound annual growth rate (CAGR) exceeding 80% over the past three years[138]. - The oral product Ruyi Zhenbao Pian has entered the national negotiation directory, achieving a CAGR of nearly 300%[138]. - The company has expanded its product portfolio in pediatrics, digestion, and cardiovascular fields through acquisitions, including the control of Tibet Tibetan Medicine Group[138]. - The company’s gynecological product Honghua Ruyi Wan has entered the national negotiation directory, providing a Tibetan medicine solution for chronic inflammatory diseases[138]. - Multiple products, including flu pills, have been included in the Tibetan medicine prevention and treatment plans for infectious respiratory diseases in several provinces, receiving clinical recognition[138]. Challenges and Risks - The company is facing challenges due to healthcare cost control and ongoing reforms in the pharmaceutical supply side, which may impact future performance[20]. - The normalization of medical insurance negotiations and the DRG/DIP system may lead to reduced drug prices and profit margins for pharmaceutical companies, posing potential profitability risks[144]. - The company emphasizes the importance of risk awareness regarding future development statements, clarifying that these do not constitute binding commitments to investors[50]. Corporate Structure and Governance - The company has 21 wholly-owned and holding subsidiaries, including GMP pharmaceutical factories and GSP marketing companies, indicating a robust operational structure[83]. - The company is recognized as a national-level high-tech enterprise and has been included in the national torch program, highlighting its innovation capabilities[83]. - The company has established independent financial management systems and ensures no interference from controlling shareholders in financial decisions[155]. - The company has set up various functional departments to ensure independent operations without interference from controlling shareholders[154]. - The company’s board includes independent directors and a diverse management team with extensive experience in the pharmaceutical industry[175][176]. - The company’s management team includes professionals with leadership roles in various pharmaceutical associations, enhancing its industry influence[175]. Employee Development and Training - In 2022, the company optimized its compensation system to maintain internal and external competitiveness, implementing a marketing bonus policy to encourage high growth and output[198]. - The company provided training programs tailored to employees' development needs, including the "Eagle 60-Day Training Camp" for new hires, with 290 participants across 5 sessions[198]. - A total of 20 individuals achieved certification as junior internal trainers through the "Internal Trainer Selection and Training" project during the reporting period[199]. Future Plans - The strategic plan for 2023-2025 is "dual-wheel drive, dual-wing leadership, dual-base guarantee"[140]. - The company is actively developing a digital shared platform to enhance overall operational efficiency and is focusing on organizational restructuring to improve leadership and attract high-quality talent[110]. - The company plans to expand its marketing network and improve its production line, with significant investments in ongoing projects[103].

证券代码：002287 证券简称：奇正藏药 编号：2016-001 西藏奇正藏药股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 光大永明资产管理股份有限公司 研究员 孙伟娜 岳苗 | | 人员姓名 | | 东兴证券股份有限公司 研究员 张金洋 胡偌碧 | | | | 方正证券股份有限公司 分析师 孔令岩 | | 时间 | 2016 年 7 月 6 | 日 11:00-12:00 | | 地点 | 北京市朝阳区北四环东路 | 131 号中国藏学研究中心 5 层公司 | | | 会议室 | | ...

证券代码：002287 证券简称：奇正藏药 编号：2020-002 西藏奇正藏药股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------------|-------------------------|----------------------------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | | 北京天蝎座资产管理有限公司副总裁贾纯冶 | | 时间 | 2020 年 7 月 14 | 日 9:00-10:00 | | 地点 | 腾讯会议 | | | 上市公司接待人 | 董事会秘书：冯平 | | | 员姓名 | 证券事务代表：李阳 | | | 投资者关系活动 | 1 | 、介绍公司基本情况 | | 主要内容介绍 | | 答：感谢您对藏药及公 ...

证券代码：002287 证券简称：奇正藏药 编号：2020-001 西藏奇正藏药股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------------|------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | | 东腾创新投资股份有限公司王安亚总经理 | | 时间 | 2020 年 6 月 9 | 日 16:00-17:00 | | 地点 | 腾讯会议 | | | 上市公司接待人 | 董事会秘书：冯平 | | | 员姓名 | 证券事务代表：李阳 | | | 投资者关系活动 | 1 | 、请介绍一下公司现在的业务模式。 | | 主要内容介绍 | | 答：感谢您对藏 ...

证券代码：002287 证券简称：奇正藏药 编号：2019-001 | --- | --- | --- | |-----------------------|-----------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 上海德韬投资有限公司 张成刚 | | | 人员姓名 | | 中银国际证券股份有限公司保定东风中路证券营业部 吕洋 | | 时间 | 2019 年 10 月 29 | 日 14:30-16:00 | | 地点 | 北京市朝阳区望京北路 | 9 号叶青大厦 D 座 7 层 | | 上市公司接待人 员姓名 | 证券事务代表：李阳 | | | 投资者关系活动 | | 证券事务代表李阳先生介绍藏医药、公司基本情况， ...

证券代码：002287 证券简称：奇正藏药 编号：2020-003 西藏奇正藏药股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|-------------------------------|--------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 中信证券资管 | 蔡霁磊 金鹰基金 蒋婉莹 | | 人员姓名 | 辰悦资本 周易 | 华能信托 张国平 | | | 合众资管 金妍 | 康曼德资本 丁楹 | | | 诚信人寿 谭丁源 | 方正证券 卢克楠 | | | 中金资管 李楠 | 华实浩瑞 王聪 | | | 益民基金 张树声 | | | 时间 | 2020 年 10 月 23 | 日 10:00-11:30 | | 地点 | 北京市西城区太平桥大街 ...

Financial Performance - The company's revenue for Q3 2022 reached ¥519,212,989.60, representing a year-on-year increase of 28.89%[5] - Net profit attributable to shareholders for the same period was ¥127,221,135.64, a significant increase of 137.34% compared to the previous year[5] - The net profit after deducting non-recurring gains and losses was ¥126,907,331.26, up by 63.37% year-on-year[5] - Basic earnings per share for Q3 2022 were ¥0.2407, an increase of 137.24% compared to the same period last year[5] - Net profit for the current period was ¥357,525,838.41, a decrease from ¥645,927,284.24, reflecting a decline of approximately 44.5%[29] - Basic earnings per share were CNY 0.6784, down from CNY 1.2247 in the previous period[32] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,457,758,867.56, a decrease of 1.98% from the end of the previous year[5] - The total assets decreased to ¥5,457,758,867.56 from ¥5,567,753,848.57, a reduction of about 2%[25] - Current liabilities totaled ¥1,084,226,284.39, down from ¥1,307,979,313.93, showing a decrease of approximately 17%[25] - Non-current liabilities increased to ¥1,105,008,433.53 from ¥1,039,391,910.81, marking an increase of about 6.3%[25] - The total equity attributable to shareholders of the parent company increased to ¥3,216,024,928.04 from ¥3,169,030,586.36, showing a growth of approximately 1.5%[25] Cash Flow - The company's cash flow from operating activities showed a significant decline, with a net amount of ¥192,374,939.97, down by 66.32% year-on-year[5] - Net cash flow from operating activities decreased by 66.32% to $192.37 million, primarily due to reduced cash received from sales and increased cash payments for employee compensation[14] - Cash inflow from operating activities totaled CNY 1,351,313,488.40, a decrease of 236,727,728.06 from CNY 1,588,041,216.46 in the previous period[33] - Net cash flow from operating activities was CNY 192,374,939.97, significantly lower than CNY 571,227,074.26 in the previous period[35] - Cash outflow from investing activities was CNY 1,397,190,085.90, compared to CNY 2,752,828,076.34 in the previous period[35] - Net cash flow from investing activities improved by 80.99% to -$279.09 million, as cash used for purchasing wealth management products decreased[14] - Cash flow from financing activities resulted in a net outflow of -CNY 399,891,357.86, compared to -CNY 207,157,680.76 in the previous period[35] Investment and Expenses - The company recognized an investment loss of ¥75,006,700.00 from its participation in a merger fund during the reporting period[9] - The financial expenses increased by 171.03% to ¥30,399,841.09 due to reduced interest income and increased loan interest[11] - The company's investment income decreased by 120.85% to -$60.75 million due to reduced long-term equity investment returns and wealth management product investment income[14] - The company reported a significant decline in investment income, with a loss of ¥60,752,497.46 compared to a gain of ¥291,417,294.11 in the previous period[29] - Research and development expenses for the current period were ¥46,893,261.76, compared to ¥44,393,885.66 in the previous period, reflecting an increase of approximately 5.6%[26] Shareholder Information - The total number of common shareholders at the end of the reporting period was 25,144, with the largest shareholder holding 68.75% of the shares[15] - Minority interests loss increased by 37.97% to -$2.02 million, indicating higher losses from controlled subsidiaries[14] Other Financial Metrics - The weighted average return on equity was 4.40%, reflecting a decrease of 13.85% year-on-year[5] - The company reported a loss of ¥40,062.14 from the disposal of non-current assets during the reporting period[6] - Total operating revenue for the current period reached ¥1,416,132,351.38, an increase from ¥1,189,266,190.30 in the previous period, representing a growth of approximately 19.1%[26] - Total operating costs amounted to ¥1,004,641,422.30, up from ¥844,453,879.84, indicating a rise of about 18.9%[26] - Total comprehensive income for the period amounted to CNY 361,177,638.72, a decrease of 645,729,862.64 compared to the previous period[32] - The company's cash and cash equivalents decreased significantly, impacting liquidity and operational flexibility[25] - The ending balance of cash and cash equivalents was CNY 183,676,142.50, down from CNY 726,006,732.94 in the previous period[35] Audit Information - The company did not undergo an audit for the third quarter report[37]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 896,919,361.78, representing a 14.07% increase compared to CNY 781,472,574.00 in the same period last year[28]. - The net profit attributable to shareholders of the listed company decreased by 76.49% to CNY 232,321,926.37 from CNY 988,598,441.07 in the previous year[28]. - The net cash flow from operating activities was CNY 239,262,551.02, down 59.09% from CNY 585,007,916.61 in the same period last year[28]. - Basic earnings per share dropped by 76.59% to CNY 0.4377 from CNY 1.8710 in the previous year[28]. - The weighted average return on net assets was 7.18%, down from 32.05% in the previous year[28]. - The company reported a decrease in diluted earnings per share by 76.13% to CNY 0.4372 from CNY 1.8322 in the previous year[28]. - The company's operating profit for the same period was 251.16 million yuan, a significant decrease of 76.94% year-on-year, primarily due to fluctuations in the stock price of Qingdao Baiyang Pharmaceutical[61]. - The net profit attributable to shareholders, after excluding non-recurring gains and losses, was 246.11 million yuan, reflecting a year-on-year increase of 4.11%[61]. Assets and Investments - Total assets at the end of the reporting period were CNY 5,625,570,431.10, a 1.04% increase from CNY 5,567,753,848.57 at the end of the previous year[28]. - The net assets attributable to shareholders of the listed company decreased by 2.63% to CNY 3,085,559,918.91 from CNY 3,169,030,586.36 at the end of the previous year[28]. - The company's investment income was -CNY 80,752,962.89, accounting for -32.17% of total profit, indicating a loss from long-term equity investments and financial products[79]. - The company's long-term equity investments decreased to CNY 454,079,507.15, representing 8.07% of total assets, down from 9.79% at the end of the previous year[82]. - The total amount of funds raised in 2009 was ¥45,120.01 million, with ¥40,369.74 million cumulatively used, leaving ¥4,750.27 million unused[97]. - The total amount of raised funds is 131,096.54 million, with 58,473.96 million used for various projects[107]. Government Support and Subsidies - The company received government subsidies amounting to CNY 58,960,681.43 during the reporting period[31]. - The company received government subsidies and deferred income of CNY 59,131,829.31, accounting for 23.56% of total profit[79]. Research and Development - Research and development expenses were ¥46,761,662.80, a slight increase of 1.53% compared to ¥46,058,231.99 in the previous year[75]. - The company continues to focus on the research and development of new Tibetan medicine products, emphasizing clinical value and the study of specific Tibetan medical theories[54]. - The company is actively pursuing digital marketing transformation and expanding e-commerce sales channels to capture future growth opportunities[56]. - The company plans to enhance brand competitiveness and clinical value through refined management and the establishment of independent academic promotion teams[118]. - The company will increase investment in R&D, focusing on new drugs with clear clinical value, while addressing risks associated with clinical research personnel turnover[119]. Marketing and Sales - The company operates a self-marketing model with over 1,600 sales personnel across more than 30 provinces, focusing on both urban hospitals and grassroots medical institutions[56]. - The company continues to focus on enhancing brand awareness in the retail market, particularly among young consumers, through various marketing initiatives[66]. - The company is leveraging digital marketing and online platforms to enhance product recognition and ensure multi-channel access for patients[122]. Social Responsibility and Compliance - The company has actively participated in social responsibility initiatives, donating 5.1679 million yuan to various poverty alleviation projects[145]. - The company has implemented environmental monitoring and has not faced any administrative penalties for environmental issues during the reporting period[141]. - The company has maintained compliance with environmental standards, with wastewater discharge meeting the required standards[141]. Shareholder Actions - The company plans not to distribute cash dividends or bonus shares for this period[7]. - The company approved the release of 7,200 restricted shares, representing 0.0014% of total shares, as part of its 2019 stock incentive plan[130]. - The company plans to repurchase and cancel 15,785 restricted shares due to non-compliance with performance conditions by certain incentive recipients[131]. - The company completed the repurchase and cancellation of unvested restricted shares on June 28, 2022[136]. Risks and Challenges - The company faces risks from ongoing national healthcare reforms, including the normalization of bulk purchasing policies, which may reduce profit margins on drugs[115]. - The ongoing pandemic has negatively impacted the company's operations, leading to decreased hospital visits and drug demand, prompting adjustments in marketing and distribution strategies[120].